Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel

SUMMARY: Background: Strong P2Y(12) blockade, as can be achieved with novel anti-platelet agents such as prasugrel, has been shown in vitro to inhibit both ADP and thromboxane A(2)-mediated pathways of platelet aggregation, calling into question the need for the concomitant use of aspirin. Objective...

Descripción completa

Detalles Bibliográficos
Autores principales: LEADBEATER, P D M, KIRKBY, N S, THOMAS, S, DHANJI, A-R, TUCKER, A T, MILNE, G L, MITCHELL, J A, WARNER, T D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338354/
https://www.ncbi.nlm.nih.gov/pubmed/21794076
http://dx.doi.org/10.1111/j.1538-7836.2011.04450.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338354/
https://www.ncbi.nlm.nih.gov/pubmed/21794076
http://dx.doi.org/10.1111/j.1538-7836.2011.04450.x

Ejemplares similares